J Bischoff1, S Mauss2, C Cordes3, T Lutz4, S Scholten5, A Moll6, H Jäger7, M Cornberg8, M P Manns8, A Baumgarten9, J K Rockstroh1. 1. Department of Medicine I, University Hospital Bonn, Bonn, Germany. 2. Center for HIV and Hepatogastroenterology, Duesseldorf, Germany. 3. Praxis Dr. Cordes, Berlin, Germany. 4. Infektiologikum, Frankfurt, Germany. 5. Dr. Scholten und Schneeweiß GbR, Köln, Germany. 6. Praxiszentrum Kaiserdamm, Berlin, Germany. 7. MVZ Karlsplatz, Munich, Germany. 8. Hannover Medical School, Hannover, Germany. 9. Center for Infectious Diseases, Berlin, Prenzlauer Berg, Germany.
Abstract
OBJECTIVES: The European Association for the Study of the Liver (EASL) treatment recommendations for hepatitis C no longer discriminate between HIV/hepatitis C virus (HCV)-coinfected and HCV-monoinfected patients. However, recent data from Spain are questioning these recommendations on the basis of the findings of higher relapse rates and lower cure rates in HIV/HCV-infected subjects. The aim of our study was to compare HCV cure rates in monoinfected and coinfected patients from Germany. METHODS: Data acquired from the Deutsches Hepatitis C-Registry were analysed. A total of 5657 HCV-monoinfected subjects and 488 HIV/HCV-coinfected patients were included in the study. Rates of sustained virological response 12 weeks after the scheduled end of therapy (SVR12) were collected in both subgroups and in cirrhotic and noncirrhotic patients. RESULTS: HIV/HCV-coinfected patients were more frequently male (84.6% vs. 56.4%, respectively; P < 0.001) and younger than HCV-monoinfected subjects (46.5 ± 9 vs. 53.8 ± 12.5 years, respectively; P < 0.001). The CD4 blood cell count was > 350 cells/μL in 63.1% of HIV-positive subjects and 88.7% were on antiretroviral therapy. SVR12 rates were 90.3% (5111 of 5657) in our HCV-monoinfected cohort and 91.2% (445 of 488) in our coinfected patients. Liver cirrhosis was confirmed in 1667 of 5657 (29.5%) monoinfected patients and 84 of 488 (17.2%; P < 0.001) coinfected patients. SVR12 rates did not differ between HCV-monoinfected and HIV/HCV-coinfected patients with liver cirrhosis (87.8% vs. 89.3%, respectively; P = 0.864). A treatment duration of 8 weeks did not reduce the percentage of patients with SVR12 in either subgroup (93.7% in both groups). CONCLUSIONS: We found high SVR12 rates in monoinfected as well as coinfected individuals. No differences were detected between the two subgroups regardless of whether there was accompanying liver cirrhosis or a shortened treatment duration.
OBJECTIVES: The European Association for the Study of the Liver (EASL) treatment recommendations for hepatitis C no longer discriminate between HIV/hepatitis C virus (HCV)-coinfected and HCV-monoinfected patients. However, recent data from Spain are questioning these recommendations on the basis of the findings of higher relapse rates and lower cure rates in HIV/HCV-infected subjects. The aim of our study was to compare HCV cure rates in monoinfected and coinfected patients from Germany. METHODS: Data acquired from the Deutsches Hepatitis C-Registry were analysed. A total of 5657 HCV-monoinfected subjects and 488 HIV/HCV-coinfectedpatients were included in the study. Rates of sustained virological response 12 weeks after the scheduled end of therapy (SVR12) were collected in both subgroups and in cirrhotic and noncirrhotic patients. RESULTS:HIV/HCV-coinfectedpatients were more frequently male (84.6% vs. 56.4%, respectively; P < 0.001) and younger than HCV-monoinfected subjects (46.5 ± 9 vs. 53.8 ± 12.5 years, respectively; P < 0.001). The CD4 blood cell count was > 350 cells/μL in 63.1% of HIV-positive subjects and 88.7% were on antiretroviral therapy. SVR12 rates were 90.3% (5111 of 5657) in our HCV-monoinfected cohort and 91.2% (445 of 488) in our coinfected patients. Liver cirrhosis was confirmed in 1667 of 5657 (29.5%) monoinfected patients and 84 of 488 (17.2%; P < 0.001) coinfected patients. SVR12 rates did not differ between HCV-monoinfected and HIV/HCV-coinfectedpatients with liver cirrhosis (87.8% vs. 89.3%, respectively; P = 0.864). A treatment duration of 8 weeks did not reduce the percentage of patients with SVR12 in either subgroup (93.7% in both groups). CONCLUSIONS: We found high SVR12 rates in monoinfected as well as coinfected individuals. No differences were detected between the two subgroups regardless of whether there was accompanying liver cirrhosis or a shortened treatment duration.
Authors: Mei Lu; Kuan-Han Wu; Jia Li; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Loralee B Rupp; Talan Zhang; Sheri Trudeau; Stuart C Gordon Journal: J Viral Hepat Date: 2019-07-04 Impact factor: 3.728
Authors: Juan Berenguer; José Luis Calleja; María Luisa Montes; Ángela Gil; Ana Moreno; Rafael Bañares; Teresa Aldámiz-Echevarría; Agustín Albillos; María Jesús Téllez; Antonio Olveira; Lourdes Domínguez; Inmaculada Fernández; Javier García-Samaniego; Benjamín A Polo; Beatriz Álvarez; Pablo Ryan; José Barrio; María J Devesa; Laura Benítez; Ignacio Santos; Luisa García Buey; José Sanz; Elvira Poves; Juan E Losa; Conrado Fernández-Rodríguez; Inmaculada Jarrín; María J Calvo; Juan González-García Journal: Open Forum Infect Dis Date: 2019-05-07 Impact factor: 3.835
Authors: Edward R Cachay; Alvaro Mena; Luis Morano; Laura Benitez; Ivana Maida; Craig Ballard; Lucas Hill; Francesca Torriani; Angeles Castro; Elena Dore; Sheila Castro; Carmen de Mendoza Fernández; Vicente Soriano; Wm C Mathews Journal: Open Forum Infect Dis Date: 2019-02-11 Impact factor: 3.835
Authors: H Nina Kim; Robin M Nance; Jessica S Williams-Nguyen; J A Chris Delaney; Heidi M Crane; Edward R Cachay; Jeffrey Martin; W Christopher Mathews; Geetanjali Chander; Ricardo Franco; Christopher B Hurt; Elvin H Geng; Benigno Rodriguez; Richard D Moore; Michael S Saag; Mari M Kitahata Journal: Open Forum Infect Dis Date: 2019-03-23 Impact factor: 3.835
Authors: Lauren P Jatt; Malini M Gandhi; Rong Guo; Adam Sukhija-Cohen; Debika Bhattacharya; Chi-Hong Tseng; Kara W Chew Journal: J Gastroenterol Hepatol Date: 2020-09-08 Impact factor: 4.029
Authors: Soraia M Machado; Aline G Vigani; Andrea G Leite; Ana Claudia M Diaz; Paulo Roberto A Ferreira; Dimas Carnaúba-Júnior; Simone B Tenore; Carlos Eduardo Brandão-Mello; Mario P Gonzalez; Fabiana Siroma; Kleber D Prado; Delzi V Nunes; Gaspar Lisboa-Neto; João Renato R Pinho; Fernanda M Malta; Raymundo S Azevedo; Steven S Witkin; Maria Cássia Mendes-Correa Journal: Medicine (Baltimore) Date: 2020-07-24 Impact factor: 1.817